Ipamorelin: Tested Once in Humans, for Something Nobody Markets It For

What ipamorelin is

Ipamorelin is a synthetic pentapeptide that acts at the growth hormone secretagogue receptor — the same pituitary receptor the body’s own ghrelin binds — producing a short pulse of growth hormone release. It was characterised at Novo Nordisk as the first selective growth hormone secretagogue, meaning that unlike GHRP-6 and GHRP-2 it did not raise cortisol in the animal models tested.

What it was actually developed for

Not anti-ageing, and not body composition. After licensing, ipamorelin was developed for postoperative ileus — the temporary shutdown of gut motility after abdominal surgery. That is the only condition it has been tested for in humans in a controlled trial, and the programme was discontinued after Phase 2. It never reached Phase 3.

What the human trials found

A randomised placebo-controlled Phase 2 trial in bowel-resection patients reported a median time to first tolerated meal of 25.3 hours against 32.6 hours on placebo — a difference that did not reach statistical significance at p = 0.15. The authors concluded there were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses. A larger dose-finding Phase 2 completed in 2014 has posted no results and no publication has been located.

What is known about the marketed uses

There are no human trials of ipamorelin for body composition, lean mass, fat loss, sleep quality, bone density or anti-ageing. The bone and body-composition findings cited in marketing are rat studies. Human pharmacokinetic work does establish that ipamorelin raises growth hormone in people — but that is a biomarker moving, not a clinical outcome, and no trial has linked the two.

What FDA says about safety

FDA’s published entry states that a study in the literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility, and that the agency has not identified safety information for other injectable routes — the routes used outside hospitals. FDA also notes ipamorelin contains unnatural amino acids, which complicates characterisation, and flags immunogenicity risk from aggregation and peptide-related impurities.

How far up the evidence hierarchy this reaches

Genuine registered human trials exist — but only in postoperative ileus, and the published one missed its endpoint. For every marketed use, the evidence drops to tier 2.

Where it sits on the compounding pathway

What it is sold for, against what the evidence shows

Marketing claims on the left, in the terms sellers use. What the human literature actually supports on the right.

Where to go next